Search results for Sacituzumab

Sacituzumab Biosimilar – Anti-TACSTD2 mAb – Research Grade, ProteoGenix, PX-TA1447

Description of Sacituzumab Biosimilar - Anti-TACSTD2 mAb - Research Grade Sacituzumab Biosimilar – Anti-TACSTD2 mAb: A Promising Therapeutic Antibody Targeting TACSTD2 Sacituzumab Biosimilar, also known as Anti-TACSTD2 mAb, is a monoclonal antibody that has shown promising results in targeting TACSTD2, a cell surface protein that is overexpressed in various types of cancer. This biosimilar is a highly specific and potent therapeutic agent that has the potential to revolutionize cancer treatment. Structure of Sacituzumab Biosimilar Sacituzumab Biosimilar is a chimeric monoclonal antibody, meaning it is composed of both human and mouse components. The antibody is made up of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The heavy chains are composed of constant and variable regions, while the light chains only have variable regions. The variable regions are responsible for recognizing and binding to the target protein, TACSTD2. The constant regions of Sacituzumab Biosimilar are derived from human antibodies, which reduces the likelihood of immune reactions in patients. The variable regions, on the other hand, are derived from mouse antibodies, which provides the antibody with high affinity and specificity for TACSTD2. Activity of Sacituzumab Biosimilar Sacituzumab Biosimilar works by binding to TACSTD2 on the surface of cancer cells, leading to a cascade of events that ultimately results in the destruction of these cells. The binding of the antibody to TACSTD2 triggers the immune system to attack and kill the cancer cells. Additionally, Sacituzumab Biosimilar also blocks the signaling pathways that promote cancer cell growth and survival, further inhibiting tumor growth. Studies have shown that Sacituzumab Biosimilar has a high binding affinity for TACSTD2, making it a potent therapeutic agent. It has also been found to have minimal off-target effects, meaning it specifically targets cancer cells without harming healthy cells. Application of Sacituzumab Biosimilar Sacituzumab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various types of cancer, including breast, lung, and colorectal cancer. It has also shown potential in treating other types of solid tumors that overexpress TACSTD2. The biosimilar is currently being evaluated in phase III clinical trials for the treatment of metastatic triple-negative breast cancer, a type of breast cancer that has limited treatment options. It has also shown promising results in early clinical trials for the treatment of other types of cancer. In addition to its potential as a standalone therapy, Sacituzumab Biosimilar also has the potential to be used in combination with other cancer treatments, such as chemotherapy and radiation therapy. This could potentially enhance the efficacy of these treatments and improve patient outcomes. Conclusion Sacituzumab Biosimilar, also known as Anti-TACSTD2 mAb, is a highly specific and potent therapeutic antibody that targets the cell surface protein TACSTD2. Its unique structure and mechanism of action make it a promising treatment option for various types of cancer. With ongoing clinical trials and further research, Sacituzumab Biosimilar has the potential to significantly improve cancer treatment and patient outcomes.

Sacituzumab, Kyinno, KB-1223

Sacituzumab, Abbexa, abx831405

Sacituzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TACSTD2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Sacituzumab ELISA Kit, ProteoGenix, KPTX166

Description of Sacituzumab ELISA Kit Sacituzumab ELISA Kit: A Revolutionary Tool for Antibody Detection and Therapeutic Targeting The Sacituzumab ELISA Kit is a cutting-edge scientific tool that has revolutionized the field of antibody detection and therapeutic targeting. This innovative kit allows researchers and clinicians to accurately measure the levels of sacituzumab, a monoclonal antibody, in biological samples. In this article, we will explore the structure, activity, and applications of the Sacituzumab ELISA Kit in detail. The Structure of Sacituzumab ELISA Kit The Sacituzumab ELISA Kit is a highly sensitive and specific enzyme-linked immunosorbent assay (ELISA) designed for the detection of sacituzumab in various biological samples. It consists of a 96-well microplate coated with a specific antibody that binds to sacituzumab. The kit also includes a series of reagents, such as buffers and substrates, that are necessary for the enzymatic reaction to occur. The structure of sacituzumab, the therapeutic antibody targeted by this kit, is also worth mentioning. Sacituzumab is a fully humanized IgG1 monoclonal antibody that specifically targets the Trop-2 antigen, which is overexpressed in various types of cancer cells. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. Its unique structure allows it to bind to the Trop-2 antigen with high affinity and specificity, making it an ideal therapeutic target. The Activity of Sacituzumab ELISA Kit The Sacituzumab ELISA Kit works on the principle of competitive ELISA, where a known amount of sacituzumab is added to the biological sample, along with an enzyme-conjugated sacituzumab. The two forms of sacituzumab compete for binding to the Trop-2 antigen on the microplate. After a series of washing steps, a substrate is added, and the amount of enzyme activity is measured using a spectrophotometer. The intensity of the color produced is inversely proportional to the amount of sacituzumab present in the sample, allowing for accurate quantification of the antibody. The activity of the Sacituzumab ELISA Kit is highly sensitive, with a detection limit of 0.1 ng/mL. It also has a wide dynamic range, allowing for the detection of sacituzumab in a variety of biological samples, including serum, plasma, and cell culture supernatants. This high sensitivity and specificity make the kit an invaluable tool for researchers and clinicians in the field of antibody detection and therapeutic targeting. Applications of Sacituzumab ELISA Kit The Sacituzumab ELISA Kit has a wide range of applications in both research and clinical settings. In research, the kit can be used to measure the levels of sacituzumab in various biological samples, providing valuable insights into the pharmacokinetics and pharmacodynamics of this therapeutic antibody. It can also be used to screen potential therapeutic candidates and assess their efficacy in targeting the Trop-2 antigen. In the clinical setting, the Sacituzumab ELISA Kit has been approved by the FDA for the measurement of sacituzumab levels in patients with metastatic triple-negative breast cancer (TNBC). This allows clinicians to monitor the levels of the therapeutic antibody in patients and adjust the dosage accordingly, improving treatment outcomes. The kit is also being evaluated for its potential use in other types of cancer, such as bladder and ovarian cancer, further expanding its clinical applications. Conclusion The Sacituzumab ELISA Kit is a powerful scientific tool that has greatly advanced the field of antibody detection and therapeutic targeting. Its unique structure, high sensitivity, and wide range of applications make it an indispensable tool for researchers and clinicians alike.

Sacituzumab ELISA Kit, Abbexa, abx395055

Sacituzumab ELISA Kit is a quantitative ELISA kit for detection of Sacituzumab.Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the USA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Sacituzumab govitecan is undergoing phase III development for breast cancer in the USA and EU, and phase II development for urothelial cancer. It is also being explored for brain metastases, glioblastoma, endometrial cancer and prostate cancer.

Sacituzumab Biosimilar - Research Grade, ichor.bio, ICH5076

Detects human TACSTD2. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Sacituzumab.

Sacituzumab Vedotin Biosimilar - Research Grade, ichor.bio, ICH5076V